Eli Lilly and Co (LLY.N)
4 Mar 2015
- A federal judge has ruled that a former manager at drug company Eli Lilly & Co is entitled to long-term disability benefits because she has fibromyalgia, overruling a determination by the company's disability plan.
Jan 30 - U.S. drugmaker Eli Lilly and Co reported a 41 percent fall in quarterly profit, hurt by a stronger dollar and a one-time charge related to a restructuring program.
- Eli Lilly and Co forecast 2015 earnings and revenue just shy of market expectations as the drugmaker looks to bounce back after the expiration of patents on some of its biggest sellers.
Jan 7 - Eli Lilly and Co, which has been battered in the past three years by competition from generics, forecast 2015 revenue shy of Wall Street expectations.
* Announces closing of Sentinel brands family acquisition in United States from Eli Lilly
WASHINGTON, Dec 22 - Eli Lilly and Co has won approval to buy Novartis AG's animal health unit on condition that it divest the Sentinel line of products for treating heartworm in dogs, the Federal Trade Commission said on Monday.
PARIS - U.S. drugmaker Eli Lilly and French biotech Adocia said on Friday they agreed a worldwide licensing partnership to develop an ultra-rapid insulin to treat patients with Type 1 and Type 2 diabetes.
PARIS, Dec 19 - U.S. drugmaker Eli Lilly and French biotech Adocia said on Friday they agreed a worldwide licensing partnership to develop ultra-rapid insulin to treat patients with Type 1 and Type 2 diabetes.
- The European Commission has granted marketing approval to Eli Lilly and Co's injectable Trulicity treatment for adults with type 2 diabetes, the U.S. drugmaker said on Tuesday.
Nov 25 - The European Commission has granted marketing approval to Eli Lilly and Co's injectable Trulicity treatment for adults with type 2 diabetes, the U.S. drugmaker said on Tuesday.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥6,525||+135.00|
|Johnson & Johnson (JNJ.N)||$101.65||-0.69|
|Pfizer Inc. (PFE.N)||$34.64||+0.08|
|Novartis AG (NOVN.VX)||CHF95.20||--|
|Merck & Co., Inc. (MRK.N)||$57.88||-0.46|
|Abbott Laboratories (ABT.N)||$47.01||-0.08|
|Sanofi SA (SASY.PA)||€87.45||--|
|AstraZeneca plc (AZN.L)||4,423.50p||-8.00|
|GlaxoSmithKline plc (GSK.L)||1,566.00p||+15.00|
|Bristol-Myers Squibb Co (BMY.N)||$65.67||+3.75|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Trading Report for (LLY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: New Constructs, LLC
"The Economy Matters" Report for LLY: the economy's impact on LLY's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.